{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T18:00:49Z","timestamp":1770487249414,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T00:00:00Z","timestamp":1578960000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T00:00:00Z","timestamp":1578960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Ophthalmol Rep"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s40135-020-00225-1","type":"journal-article","created":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T02:02:20Z","timestamp":1578967340000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A New Approach for Diabetic Macular Edema Treatment: Review of Clinical Practice Results with 0.19\u00a0mg Fluocinolone Acetonide Intravitreal Implant Including Vitrectomized Eyes"],"prefix":"10.1007","volume":"8","author":[{"given":"Raquel","family":"Estebainha","sequence":"first","affiliation":[]},{"given":"Raquel","family":"Goldhardt","sequence":"additional","affiliation":[]},{"given":"Manuel","family":"Falc\u00e3o","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,1,14]]},"reference":[{"key":"225_CR1","unstructured":"The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;150218140025008."},{"issue":"14","key":"225_CR2","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1080\/14656566.2017.1363182","volume":"18","author":"D Veritti","year":"2017","unstructured":"Veritti D, Sarao V, Diplotti L, Samassa F, Lanzetta P. Fluocinolone acetonide for the treatment of diabetic macular edema. Expert Opin Pharmacother. 2017 Oct;18(14):1507\u201316.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"225_CR3","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40265-017-0722-4","volume":"77","author":"YY Syed","year":"2017","unstructured":"Syed YY. Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN\u00ae): a review in diabetic macular edema. Drugs. 2017;77(5):575\u201383.","journal-title":"Drugs."},{"issue":"3","key":"225_CR4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/14656566.2017.1363182","volume":"9","author":"C Haritoglou","year":"2016","unstructured":"Haritoglou C, Mayer W, Wolf A. Fluocinolone acetonide for the treatment of diabetic macular edema. Expert Rev Clin Pharmacol. 2016;9(3):367\u201374. https:\/\/doi.org\/10.1080\/14656566.2017.1363182.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"225_CR5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JWY Yau","year":"2012","unstructured":"Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556\u201364 Available from: http:\/\/care.diabetesjournals.org\/cgi\/doi\/10.2337\/dc11-1909.","journal-title":"Diabetes Care"},{"issue":"1","key":"225_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0161-6420(95)31052-4","volume":"102","author":"R Klein","year":"1995","unstructured":"Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XV: the long-term incidence of macular edema. Ophthalmology. 1995;102(1):7\u201316. https:\/\/doi.org\/10.1016\/S0161-6420(95)31052-4.","journal-title":"Ophthalmology"},{"key":"225_CR7","first-page":"2008","volume":"3","author":"D Minassian","year":"2010","unstructured":"Minassian D, Owens D, Reidy AMP. Diabetic macular oedema and related sight loss at first screening for eye disease. The Wales Diabetic Retinopathy Screening Service (WDRSS). UK Vision Strategy. 2010;3:2008.","journal-title":"UK Vision Strategy"},{"issue":"1","key":"225_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40123-016-0045-7","volume":"5","author":"I Elaraoud","year":"2016","unstructured":"Elaraoud I, Attawan A, Quhill F. Case series investigating the efficacy and safety of bilateral fluocinolone acetonide (ILUVIEN\u00ae) in patients with diabetic macular edema. Ophthalmol Therapy. 2016;5(1):95\u2013104.","journal-title":"Ophthalmol Therapy"},{"issue":"Suppl(August 19","key":"225_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/0039-6257(84)90227-3","volume":"28","author":"FL Ferris","year":"1984","unstructured":"Ferris FL, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol. 1984;28(Suppl(August 1986)):452\u201361.","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"225_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000362764","volume":"52","author":"F Bandello","year":"2014","unstructured":"Bandello F, Preziosa C, Querques G, Lattanzio R. Update of intravitreal steroids for the treatment of diabetic macular edema. Ophthalmic Res. 2014;52(2):89\u201396.","journal-title":"Ophthalmic Res"},{"key":"225_CR11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2147\/OPTH.S34057","volume":"7","author":"C Haritoglou","year":"2013","unstructured":"Haritoglou C, Neubauer AS, Kernt M. Fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema. Clin Ophthalmol. 2013;7:503\u20139 Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3595182&tool=pmcentrez&rendertype=abstract.","journal-title":"Clin Ophthalmol"},{"issue":"11","key":"225_CR12","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1016\/j.ophtha.2009.04.023","volume":"116","author":"QD Nguyen","year":"2009","unstructured":"Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology. 2009;116(11):2175\u20132181.e1 Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642009004102.","journal-title":"Ophthalmology"},{"issue":"11","key":"225_CR13","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","volume":"121","author":"JF Korobelnik","year":"2014","unstructured":"Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247\u201354.","journal-title":"Ophthalmology."},{"issue":"8","key":"225_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaophthalmol.2016.1669","volume":"134","author":"EL Ross","year":"2016","unstructured":"Ross EL, Hutton DW, Stein JD, Bressler NM, Jampol LM, Glassman AR, et al. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment. JAMA Ophthalmol. 2016;134(8):1\u201310.","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"225_CR15","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.ophtha.2015.03.024","volume":"122","author":"A Das","year":"2015","unstructured":"Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 2015;122(7):1375\u201394. https:\/\/doi.org\/10.1016\/j.ophtha.2015.03.024.","journal-title":"Ophthalmology"},{"key":"225_CR16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2147\/OPTH.S131165","volume":"11","author":"H Saedon","year":"2017","unstructured":"Saedon H, Anand A, Yang YC. Clinical utility of intravitreal fluocinolone acetonide (Iluvien\u00ae) implant in the management of patients with chronic diabetic macular edema: a review of the current literature. Clin Ophthalmol. 2017;11:583\u201390.","journal-title":"Clin Ophthalmol"},{"issue":"10","key":"225_CR17","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","volume":"120","author":"DM Brown","year":"2013","unstructured":"Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013\u201322. https:\/\/doi.org\/10.1016\/j.ophtha.2013.02.034.","journal-title":"Ophthalmology"},{"issue":"13","key":"225_CR18","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s40265-015-0447-1","volume":"75","author":"P Calvo","year":"2015","unstructured":"Calvo P, Abadia B, Ferreras A, Ruiz-Moreno O, Verdes G, Pablo LE. Diabetic macular edema: options for adjunct therapy. Drugs. 2015;75(13):1461\u20139.","journal-title":"Drugs."},{"issue":"1","key":"225_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40123-016-0049-3","volume":"5","author":"I Elaraoud","year":"2016","unstructured":"Elaraoud I, Quhill H, Quhill F. Case series investigating the efficacy and safety of bilateral fluocinolone acetonide (ILUVIEN\u00ae) in patients with diabetic macular edema: 10 eyes with 12 months follow-up. Ophthalmol Therapy. 2016;5(1):105\u20139.","journal-title":"Ophthalmol Therapy"},{"issue":"3","key":"225_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1159\/000455235","volume":"57","author":"J Figueira","year":"2017","unstructured":"Figueira J, Henriques J, Amaro M, Rosas V, Alves D, Cunha-Vaz J. A nonrandomized, open-label, multicenter, phase 4 pilot study on the effect and safety of ILUVIEN\u00ae in chronic diabetic macular edema patients considered insufficiently responsive to available therapies (RESPOND). Ophthalmic Res. 2017;57(3):166\u201372.","journal-title":"Ophthalmic Res"},{"key":"225_CR21","doi-asserted-by":"crossref","unstructured":"Daruich A, Matet A, Behar-Cohen F. Sustained-release steroids for the treatment of diabetic macular edema. Curr Diab Rep. 2015;15(11).","DOI":"10.1007\/s11892-015-0669-3"},{"key":"225_CR22","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.2147\/OPTH.S105385","volume":"10","author":"P Massin","year":"2016","unstructured":"Massin P, Erginay A, Dupas B, Couturier A, Tadayoni R. Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study. Clin Ophthalmol. 2016;10:1257\u201364.","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"225_CR23","doi-asserted-by":"publisher","first-page":"156","DOI":"10.4274\/tjo.56338","volume":"47","author":"B Nur\u00f6zler Tabakc\u0131","year":"2017","unstructured":"Nur\u00f6zler Tabakc\u0131 B, \u00dcnl\u00fc N. Corticosteroid treatment in diabetic macular edema. T\u00fcrk Oftalmol Derg. 2017;47(3):156\u201360 Available from: http:\/\/cms.galenos.com.tr\/FileIssue\/6\/1205\/article\/156-160-ing.pdf.","journal-title":"T\u00fcrk Oftalmol Derg"},{"issue":"4","key":"225_CR24","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.ajo.2004.10.063","volume":"139","author":"Diana V. Do","year":"2005","unstructured":"Do D V., Shah SM, Sung JU, Haller JA, Nguyen QD. Persistent diabetic macular edema is associated with elevated hemoglobin A1c. Am J Ophthalmol. 2005 [cited 2018 Aug 22];139(4):620\u20133. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15808156.","journal-title":"American Journal of Ophthalmology"},{"issue":"3","key":"225_CR25","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1517\/14712598.2016.1131265","volume":"16","author":"RM Hussain","year":"2016","unstructured":"Hussain RM, Ciulla TA. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy. Expert Opin Biol Ther. 2016;16(3):365\u201374 Available from: http:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14712598.2016.1131265.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"225_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/1874382601003010030","volume":"3","author":"M Falcao","year":"2012","unstructured":"Falcao M. Diabetic retinopathy: understanding pathologic angiogenesis and exploring its treatment options. Open Circ Vasc J. 2012;3(1):30\u201342.","journal-title":"Open Circ Vasc J"},{"issue":"April","key":"225_CR27","first-page":"1734","volume":"19","author":"N Dong","year":"2013","unstructured":"Dong N, Xu B, Wang B, Chu L. Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy. Mol Vis. 2013;19(April):1734\u201346 Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3733907&tool=pmcentrez&rendertype=abstract.","journal-title":"Mol Vis"},{"issue":"4","key":"225_CR28","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s11892-012-0281-8","volume":"12","author":"MW Stewart","year":"2012","unstructured":"Stewart MW. Corticosteroid use for diabetic macular edema: old fad or new trend? Curr Diab Rep. 2012;12(4):364\u201375.","journal-title":"Curr Diab Rep"},{"key":"225_CR29","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.2147\/OPTH.S115546","volume":"10","author":"SG Schwartz","year":"2016","unstructured":"Schwartz SG, Scott IU, Stewart MW, Flynn HW. Update on corticosteroids for diabetic macular edema. Clin Ophthalmol. 2016;10:1723\u201330.","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"225_CR30","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ophtha.2012.09.014","volume":"120","author":"PA Campochiaro","year":"2013","unstructured":"Campochiaro PA, Nguyen QD, Hafiz G, Bloom S, Brown DM, Busquets M, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120(3):583\u20137. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.014.","journal-title":"Ophthalmology"},{"issue":"2","key":"225_CR31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1159\/000484091","volume":"59","author":"Bernardete Pessoa","year":"2017","unstructured":"Pessoa B, Coelho J, Correia N, Ferreira N, Beir\u00e3o M, Meireles A. Fluocinolone acetonide intravitreal implant 190 \u03bcg (ILUVIEN\u00ae) in vitrectomized versus nonvitrectomized eyes for the treatment of chronic diabetic macular edema. Ophthalmic Res. 2018 [cited 2018 Aug 23];59(2):68\u201375. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29248913.","journal-title":"Ophthalmic Research"},{"issue":"5","key":"225_CR32","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/eye.2016.303","volume":"31","author":"A Meireles","year":"2017","unstructured":"Meireles A, Goldsmith C, El-Ghrably I, Erginay A, Habib M, Pessoa B, et al. Efficacy of 0.2 \u03bcg\/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy. Eye. 2017;31(5):684\u201390. https:\/\/doi.org\/10.1038\/eye.2016.303.","journal-title":"Eye"},{"issue":"7","key":"225_CR33","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.ophtha.2009.11.024","volume":"117","author":"PA Campochiaro","year":"2010","unstructured":"Campochiaro PA, Hafiz G, Shah SM, Bloom S, Brown DM, Busquets M, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology. 2010;117(7):1393\u20131399.e3. https:\/\/doi.org\/10.1016\/j.ophtha.2009.11.024.","journal-title":"Ophthalmology"},{"issue":"4","key":"225_CR34","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.ophtha.2010.12.028","volume":"118","author":"PA Campochiaro","year":"2011","unstructured":"Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626\u2013635.e2 Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642010013813.","journal-title":"Ophthalmology"},{"issue":"10","key":"225_CR35","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","volume":"119","author":"PA Campochiaro","year":"2012","unstructured":"Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125\u201332. https:\/\/doi.org\/10.1016\/j.ophtha.2012.04.030.","journal-title":"Ophthalmology"},{"issue":"4","key":"225_CR36","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.ophtha.2016.11.034","volume":"124","author":"CC Wykoff","year":"2017","unstructured":"Wykoff CC, Chakravarthy U, Campochiaro PA, Bailey C, Green K, Cunha-Vaz J. Long-term effects of intravitreal 0.19 mg fluocinolone acetonide implant on progression and regression of diabetic retinopathy. Ophthalmology. 2017;124(4):440\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2016.11.034.","journal-title":"Ophthalmology"},{"issue":"3","key":"225_CR37","doi-asserted-by":"publisher","first-page":"357","DOI":"10.5301\/ejo.5000929","volume":"27","author":"I El-Ghrably","year":"2017","unstructured":"El-Ghrably I, Steel DHW, Habib M, Vaideanu-Collins D, Manvikar S, Hillier RJ. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 \u03bcg\/d intravitreal implant: real-world UK experience. Eur J Ophthalmol. 2017;27(3):357\u201362.","journal-title":"Eur J Ophthalmol"},{"key":"225_CR38","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2147\/OPTH.S79785","volume":"9","author":"VK Schmit-Eilenberger","year":"2015","unstructured":"Schmit-Eilenberger VK. A novel intravitreal fluocinolone acetonide implant (Iluvien(R)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series. Clin Ophthalmol. 2015;9:801\u201311.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"225_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12886-015-0178-9","volume":"16","author":"I Elaraoud","year":"2016","unstructured":"Elaraoud I, Andreatta W, Kidess A, Bhatnagar A, Tsaloumas M, Quhill F, et al. Use of fluocinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting. BMC Ophthalmol. 2016;16(1):3.","journal-title":"BMC Ophthalmol"},{"issue":"12","key":"225_CR40","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1038\/eye.2017.125","volume":"31","author":"C Bailey","year":"2017","unstructured":"Bailey C, Chakravarthy U, Lotery A, Menon G, Talks J, Medisoft Audit Group. Real-world experience with 0.2 \u03bcg\/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Eye (Lond). 2017;31(12):1707\u201315.","journal-title":"Eye (Lond)"},{"key":"225_CR41","doi-asserted-by":"crossref","unstructured":"Chakravarthy U, Taylor SR, Koch FHJ, Castro de Sousa JP, Bailey C. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries. Br J Ophthalmol. 2018 21 [cited 2018 Oct 6];bjophthalmol-2018-312284. Available from: http:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2018-312284","DOI":"10.1136\/bjophthalmol-2018-312284"},{"issue":"1","key":"225_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40123-015-0028-0","volume":"4","author":"T Bertelmann","year":"2015","unstructured":"Bertelmann T, Schulze S. Long-term follow-up of patient with diabetic macular edema receiving fluocinolone acetonide intravitreal implant. Ophthalmol Therapy. 2015;4(1):51\u20138 Available from: http:\/\/link.springer.com\/10.1007\/s40123-015-0028-0.","journal-title":"Ophthalmol Therapy"},{"key":"225_CR43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/03007995.2017.1366662","volume":"33","author":"CJ Currie","year":"2017","unstructured":"Currie CJ, Holden SE, Owens DR. Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 \u03bcg intravitreal implant for diabetic macular edema. Curr Med Res Opin. 2017;33:33\u201343. https:\/\/doi.org\/10.1080\/03007995.2017.1366662.","journal-title":"Curr Med Res Opin"},{"key":"225_CR44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/03007995.2017.1366645","volume":"33","author":"SE Holden","year":"2017","unstructured":"Holden SE, Currie CJ, Owens DR. Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 \u03bcg intravitreal implant in people with diabetic macular edema. Curr Med Res Opin. 2017;33:5\u201317. https:\/\/doi.org\/10.1080\/03007995.2017.1366645.","journal-title":"Curr Med Res Opin"},{"key":"225_CR45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/03007995.2017.1366659","volume":"33","author":"CJ Currie","year":"2017","unstructured":"Currie CJ, Holden SE, Berni E, Owens DR. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 \u03bcg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. Curr Med Res Opin. 2017;33:19\u201331. https:\/\/doi.org\/10.1080\/03007995.2017.1366659.","journal-title":"Curr Med Res Opin"}],"container-title":["Current Ophthalmology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40135-020-00225-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40135-020-00225-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40135-020-00225-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T04:10:38Z","timestamp":1665461438000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40135-020-00225-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,14]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["225"],"URL":"https:\/\/doi.org\/10.1007\/s40135-020-00225-1","relation":{},"ISSN":["2167-4868"],"issn-type":[{"value":"2167-4868","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,14]]},"assertion":[{"value":"14 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Raquel Estebainha declares no potential conflicts of interest.Raquel Goldhardt is section editor of the Retina section of <i>Current Ophthalmology Reports<\/i>.Manuel Falc\u00e3o has received travel grants from Alimera, Allergan, Bayer, and Novartis and received lecture honoraria from Alimera and Bayer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}